Dexlansoprazole
| File:Dexlansoprazole structure.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
(R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole | |
| Clinical data | |
| [[Regulation of therapeutic goods |Template:Engvar data]] |
|
| Pregnancy category |
|
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 138530-94-6 |
| ATC code | none |
| Chemical data | |
| Formula | C16H14F3N3O2S |
| Molar mass | 369.363 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Dexlansoprazole (INN, trade names Kapidex, Dexilant) is a proton pump inhibitor that is marketed by Takeda Pharmaceuticals. Chemically, it is an enantiomer of lansoprazole. The compound was launched in the US for use in the treatment and maintenance of patients with erosive oesophagitis and non-erosive gastro-oesophageal reflux disease (GERD or GORD).[1] Dexlansoprazole was approved by the U.S. Food and Drug Administration (FDA) on January 30, 2009.[1]
Pharmacokinetics
After racemic lansoprazole is applied orally, 80% of the circulating drug are dexlansoprazole. Moreover, both enantiomers have a similar effect on the proton pump.[2] Consequently, the main advantage of Kapidex is not the enantiopure substance, but the pharmaceutical formulation.
Kapidex is based on a dual release technology, with the first quick release producing a plasma peak concentration about one hour after application, and the second retarded release producing another peak about four hours later.[1][3] As of November 2009[update], clinical relevance of this form of release has yet to be shown.
Naming confusion
Since Kapidex was approved in January 2009, there have been reports of dispensing errors because of confusion with the drugs Casodex (bicalutamide) and Kadian (morphine sulfate), which have very different uses from Kapidex and from each other. On March 4, 2010, the FDA has approved a name change for Kapidex to avoid confusion with the two other medications. Effective in late April 2010, Takeda Pharmaceuticals North America will market Kapidex under the new name Dexilant.[4]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />External links
- DEXILANT (product's website)
- Takeda Pharmaceuticals (manufacturer's website)
| 45px | This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it. |
- ↑ 1.0 1.1 1.2 FDA Approves KAPIDEX (dexlansoprazole) delayed release capsules for the Treatment of GERD
- ↑ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009
- ↑ Metz, DC; Vakily, M; Dixit, T; Mulford, D (1 May 2009). "Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy". Aliment Pharmacol Ther. 29 (9): 928–37. doi:10.1111/j.1365-2036.2009.03984.x. PMID 19298580.
- ↑ "KAPIDEX (dexlansoprazole) Renamed DEXILANT in U.S. to Avoid Name Confusion". Takeda. 4 March 2010. line feed character in
|title=at position 54 (help)
- Pages using duplicate arguments in template calls
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from November 2009
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- 2Fix
- Proton pump inhibitors
- Benzimidazoles
- Sulfoxides
- Pyridines
- Enantiopure drugs
- Phenol ethers
- Organofluorides
- Gastrointestinal system drug stubs
- CS1 errors: invisible characters
